Interleukin 4-receptor-α blockade in localised scleroderma: a phase 2 proof-of-concept study
Annals of the Rheumatic Diseases · 2026-10
DOI: 10.1016/j.ard.2026.09.022 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of the Rheumatic Diseases, 2026-10. Verfasst von Sabine A Eming und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Cluster of Excellence Cellular Stress Responses in Ageing-associated Diseases, Center for Molecular Medicine Cologne, Inst…. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sanofi-Aventis US LLC, University of Cologne.
Abstract (Originalsprache)
OBJECTIVES: Fibrotic diseases are a major therapeutic challenge. In humans, fibrosing diseases are often associated with an interleukin (IL-) 4/TH2 signature. In preclinical mouse models, development of fibrosis critically depends on IL-4/signal transducer and activator of transcription 6 (STAT6). Yet, the role of IL-4/IL-13 in human fibrosing diseases remains unknown, and treatment development requires a deeper understanding of the role of IL-4/IL-13 in the pathogenesis. The local inflammation and the development of fibrosis in localised scleroderma (LS) are similar to those in systemic sclerosis and other fibrosing diseases. METHODS: In this article, we investigated the role of IL-4/IL-13 signalling in LS in a randomised, placebo-controlled clinical trial (ClinicalTrials.gov registration: NCT04200755). We studied the effect of 6 months of blocking IL-4-receptor α with dupilumab on disease progression, sclerosis-associated inflammation, and sclerosis-specific gene expression. RESULTS: Already this short-term intervention resulted in a significant clinical improvement over placebo, a significant attenuation of the local inflammation, a specific and significant reduction of the IL-4/IL-13-dependent gene signature, and a partial suppression of genes coding for fibrosis-inducing proteins. CONCLUSIONS: Thus, selective inhibition of IL-4/IL-13 prevents the progression of LS and is promising for therapeutic prevention of other fibrosing diseases.
Autor:innen und Institutionen
- Department of Dermatology, Cluster of Excellence Cellular Stress Responses in Ageing-associated Diseases, Center for Molecular Medicine Cologne, Institute of Zoology, Developmental Biology, University of Cologne, Cologn…
- Department of Dermatology, University Witten/Herdecke, Witten, Germany.
- Department of Dermatology, Eberhard Karls University Tübingen, Tübingen, Germany.
- Department of Dermatology, Charité, Universitätsmedizin Berlin, Berlin, Germany.
- Department of Dermatology, University of Cologne, Cologne, Germany.
- Cologne Center for Genomics, Medical Faculty, University of Cologne, Cologne, Germany.
Förderung
- Sanofi-Aventis US LLC
- University of Cologne
Zitieren
APA
Eming, S. A., Kreuter, A., Hahn, M., Ghoreschi, K., Moinzadeh, P., Hunzelmann, N., Becker, K., Reiche, N., Adams, A., Shah-Hosseini, K., Hellmich, M., Willenborg, S., Sanin, D. E., Röcken, M., & Krieg, T. (2026). Interleukin 4-receptor-α blockade in localised scleroderma: a phase 2 proof-of-concept study. Annals of the Rheumatic Diseases. https://doi.org/10.1016/j.ard.2026.09.022
Vancouver
Eming SA, Kreuter A, Hahn M, Ghoreschi K, Moinzadeh P, Hunzelmann N, et al. Interleukin 4-receptor-α blockade in localised scleroderma: a phase 2 proof-of-concept study. Annals of the Rheumatic Diseases. 2026. doi:10.1016/j.ard.2026.09.022
BibTeX
@article{Eming2026,
author = {Eming, Sabine A and Kreuter, Alexander and Hahn, Matthias and Ghoreschi, Kamran and Moinzadeh, Pia and Hunzelmann, Nicolas and Becker, Kerstin and Reiche, Nils and Adams, Anne and Shah-Hosseini, Kija and Hellmich, Martin and Willenborg, Sebastian and Sanin, David E and Röcken, Martin and Krieg, Thomas},
title = {Interleukin 4-receptor-α blockade in localised scleroderma: a phase 2 proof-of-concept study},
journal = {Annals of the Rheumatic Diseases},
year = {2026},
doi = {10.1016/j.ard.2026.09.022}
}
EUVIMED